This article is more than 5 years old. Information may no longer be current.

Conjunctivitis test approved in Canada

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Rapid Pathogen Screening Inc. announced Tuesday that AdenoPlus has been approved for a Medical Device License in Canada.

AdenoPlus, a point-of-care test used to detect adenoviral antigens in cases of conjunctivitis, can provide results in 10 minutes from a tear sample, according to the release.

An agreement reached in 2012 granted distribution rights in Canada to Nicox.

“RPS is excited to work with Nicox to bring AdenoPlus to Canada,” Robert Sambursky, MD, chief executive officer, president and chairman of RPS, said in the release. “Studies show significant overlap in the signs and symptoms of viral and bacterial conjunctivitis, making this contagious infection difficult to diagnose clinically. Providing a rapid and accurate in-office diagnosis with AdenoPlus will save valuable time and money.”

The AdenoPlus test is currently used in Europe, Asia and the U.S., according to the release.